Efficacy and Safety Data from SunRISe-1

The pCR rate was 33% with APL-1202 plus tislelizumab compared with 26% with tislelizumab alone.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

“Among active surveillance patients, 82% are metastases free, and 60% were metastases free and had an intact, un-radiated bladder,” said Pooja Ghatalia, MD.

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.